Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Chem ; 109: 104718, 2021 04.
Article in English | MEDLINE | ID: mdl-33618257

ABSTRACT

An efficient method for the synthesis of a new class of α-aminophosphonates of imatinib derivative has been developed in one-pot Kabachnik-Fields reaction of N-(5-amino-2-methyl phenyl)-4-(3-pyridyl)-2-pyrimidine amine with various aldehydes and diethyl phosphite under microwave irradiation and neat conditions using NiO nanoparticles as an reusable and heterogeneous catalyst, with 96% yield at 450 W within 15 min. All the compounds were evaluated for their in vitro cytotoxicity with various cancer cell lines by MTT assay method. Compounds with halo (4f, -4Br, IC50 = 1.068 ± 0.88 µM to 2.033 ± 0.97 µM), nitro substitution (4 h, -3NO2, IC50 = 1.380 ± 0.94 µM to 2.213 ± 0.64 µM), (4 g, -4NO2, IC50 = 1.402 ± 0.79 µM to 2.335 ± 0.73 µM) and (4i, 4-Cl, 3-NO2, IC50 = 1.437 ± 0.92 µM to 2.558 ± 0.76 µM) were showed better anticancer activity when compared with standard drugs Doxorubicin and Imatinib using MTT assay method. Further in silico target hunting reveals the anticancer activity of the designed compounds by inhibiting human ABL tyrosine kinase and all the designed compounds have shown significant drug-like characteristics.


Subject(s)
Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Imatinib Mesylate/chemistry , Protein-Tyrosine Kinases/antagonists & inhibitors , Antineoplastic Agents/pharmacokinetics , Doxorubicin/pharmacology , Humans , Imatinib Mesylate/metabolism , Inhibitory Concentration 50 , Models, Molecular , Molecular Docking Simulation , Molecular Structure , Protein Conformation , Proto-Oncogene Proteins c-abl
2.
Biotechnol Appl Biochem ; 66(6): 977-989, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31486095

ABSTRACT

Newcastle disease virus (NDV) causes huge economic loss to the poultry industry due to high mortality and morbidity. The present study aimed to assess the protective role of novel phosphorylated analogue ABC-1 in vivo in NDV-infected chickens through the inhibition of fusion protein. Both NDV-induced oxidative damage and protective role of novel phosphorylated ABC-1 were evaluated in vital organs such as the liver and lung of chickens. Enzyme linked immunosorbent assay (ELISA) results showed that protein oxidation and nitration levels were significantly raised in NDV-infected tissues compared to healthy controls, whereas these levels were reduced significantly (P < 0.05) in birds treated with phosphorylated compounds compared to the NDV-infected group alone. Additional investigation with double immunofluorescence showed that the large amount of immuno colocalization and Western blot analysis also confirmed this observation through its band pattern in NDV-infected birds compared to healthy birds, whereas these alterations were reduced in treatment with novel phosphorylated ABC-1. The expression of fusion glycoprotein was studied by immuno colocalization, PCR, and flow cytometry, and results demonstrated that the novel phosphorylated analogues reduced the expression of fusion glycoprotein. These results put forth that novel phosphorylated ABC-1 protects chickens from NDV-induced pathogenesis, protein oxidation/nitration, and exerts potent antiviral activity.


Subject(s)
Anti-HIV Agents/pharmacology , Dideoxynucleosides/pharmacology , Newcastle disease virus/drug effects , Animals , Chickens , Microbial Sensitivity Tests , Phosphorylation
3.
Appl Biochem Biotechnol ; 180(2): 361-81, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27142273

ABSTRACT

Newcastle disease virus is the most devastating virus in poultry industry. It can eradicate the entire poultry flocks once infected. This study is aimed to investigate the antiviral efficacy of novel phosphorylated analogues of the drug abacavir (ABC) against Newcastle disease virus (NDV). About 16 analogues of ABC were designed and docking was performed against fusion protein of NDV. Three compounds were identified and selected for synthesis and biological evaluation based on binding affinity and docking scores. The compounds were synthesized and characterized by IR, (1)H, (13)C, (31)P and CHN analysis and mass spectra. These compounds were tested for antiviral efficacy against NDV-infected DF-1 cells. Compound ABC-1 had shown potent antiviral activity as evidenced by significant reduction in plaque units and cytopathic effect. Therefore, ABC-1 was selected to test for NDV-infected chicken survival rate. Effective dose50 concentrations were determined for ABC-1. Antioxidant enzyme levels in brain, liver and lung tissues were estimated. Superoxide dismutase and catalase were significantly raised and lipid peroxidation and HA titer levels were decreased upon treatment with 2 mg/kg body weight ABC-1. Histopathological modifications were also restored in the ABC-1-treated group. These findings demonstrated ABC-1 as a potential antiviral agent against NDV in chicken.


Subject(s)
Antiviral Agents/therapeutic use , Dideoxynucleosides/chemical synthesis , Dideoxynucleosides/therapeutic use , Newcastle Disease/drug therapy , Newcastle Disease/virology , Newcastle disease virus/drug effects , Animals , Antioxidants/pharmacology , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Chickens , Dideoxynucleosides/chemistry , Dideoxynucleosides/pharmacology , Hemagglutination/drug effects , Inhibitory Concentration 50 , Molecular Docking Simulation , Newcastle Disease/pathology , Phosphorylation/drug effects , Quantitative Structure-Activity Relationship , Viral Fusion Proteins/metabolism
4.
Arch Pharm (Weinheim) ; 349(6): 442-55, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27128998

ABSTRACT

A series of novel phosphorylated derivatives of didanosine were designed and docking studies were performed with a fusion protein of the Newcastle disease virus (NDV), to develop antiviral compounds against NDV. Based on the docking scores and binding affinities, three derivatives were selected. These compounds were synthesized and characterized by IR, (1) H, (13) C, (31) P, and CHN analysis and mass spectra. They were assessed for their in vitro antiviral activity in DF-1 cells; DDI-10 showed better antiviral activity as evidenced by significant reduction in plaque formation and cytopathic effects. DDI-10 was further evaluated in NDV-infected chicken; the survival rates and antioxidant enzyme levels in brain, liver, and lung tissues were estimated. Superoxide dismutase and catalase were significantly raised, and lipid peroxidation and HA titer levels were decreased upon treatment with 1.5 mg/kg body weight of DDI-10 than with 3 mg/kg body weight of DDI. Further histopathological alterations in NDV-infected tissues were restored in chicken treated with DDI-10. Thus, based on the results from in silico, in vitro, and in vivo assays, the novel phosphorylated DDI-10 might be considered as potent antiviral compound for NDV infection in chicken.


Subject(s)
Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Chickens/virology , Didanosine/analogs & derivatives , Didanosine/pharmacology , Newcastle Disease/virology , Newcastle disease virus/drug effects , Animals , Antiviral Agents/chemistry , Antiviral Agents/therapeutic use , Brain/metabolism , Catalase/metabolism , Cells, Cultured , Didanosine/chemistry , Didanosine/therapeutic use , Hemagglutination/drug effects , Lipid Peroxidation/drug effects , Liver/metabolism , Lung/metabolism , Molecular Docking Simulation , Newcastle Disease/drug therapy , Phosphorylation , Poultry Diseases/drug therapy , Poultry Diseases/virology , Quantitative Structure-Activity Relationship , Superoxide Dismutase/metabolism , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...